Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc (NDRA) pioneers advanced medical imaging through its TAEUS technology and Nexus 128 system, offering non-invasive solutions for liver diagnostics and preclinical research. This page consolidates all official announcements and third-party analyses about the company’s technological advancements and strategic initiatives.
Access real-time updates on regulatory milestones, clinical trial progress, and partnerships driving innovation in photoacoustic imaging. Investors and researchers will find detailed coverage of product developments like the TAEUS liver fat quantification system and Nexus 128’s 4D scanning capabilities.
Key updates include financial results, intellectual property filings, and collaborations with global research institutions. All content is verified for accuracy and relevance to ensure informed decision-making about this emerging leader in cost-effective diagnostic imaging.
Bookmark this page to stay informed about NDRA’s progress in addressing unmet needs in NAFLD/NASH diagnosis and expanding applications of thermo-acoustic ultrasound technology across healthcare markets.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has strengthened its intellectual property with the issuance of five new international patents, including three in Europe and two in China. This brings ENDRA's IP portfolio to a milestone of 80 issued patents worldwide, protecting its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents cover innovative solutions for providing RF energy to tissue, determining material types, and monitoring tissue temperature during surgical procedures, expanding the application of TAEUS technology.
FAQ
What is the current stock price of Endra Life Sciences (NDRA)?
What is the market cap of Endra Life Sciences (NDRA)?
